encepp

Cohort Study of Long-term Safety of Upadacitinib in the Treatment of Atopic Dermatitis in Denmark and Sweden

11/07/2023
19/05/2025
EU PAS number:
EUPAS49230
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

p20390-protocol-pmos-v4-0-Redacted.pdf

English (2.18 MB - PDF) View document
Study results
Study report
Other information
ENCePP Seal
This study has been awarded the ENCePP seal
Conflicts of interest of investigators

DoIs combined_upa AD PASS.pdf

English (2.9 MB - PDF) View document
Composition of steering group and observers

EUPAS49230-105777

English (60.64 KB - PDF) View document
Signed code of conduct

Annex3_Declaration-Upa AD PASS_signed.pdf

English (247.23 KB - PDF) View document
Signed code of conduct checklist

Annex2_Checklist-Upa AD PASS_signed.pdf

English (1.56 MB - PDF) View document
Signed checklist for study protocols

Signed ENCePP checklist for Upa AD PASS v1.0 Study Protocol.pdf

English (137.81 KB - PDF) View document